Testing the Effectiveness of a Combination Targeted Therapy (ViPOR) for Patients With Relapsed and/or Refractory Aggressive B-cell Lymphoma
National Cancer Institute (NCI)
National Cancer Institute (NCI)
M.D. Anderson Cancer Center
Genmab
Genmab
M.D. Anderson Cancer Center
Guangzhou Lupeng Pharmaceutical Company LTD.
Ruijin Hospital
Ohio State University Comprehensive Cancer Center
Henan Cancer Hospital
SWOG Cancer Research Network
Navy General Hospital, Beijing
Grupo Español de Linfomas y Transplante Autólogo de Médula Ósea
Navy General Hospital, Beijing
The First Affiliated Hospital of Xiamen University
Ruijin Hospital
Seoul National University Hospital
Ruijin Hospital
Navy General Hospital, Beijing
The First Affiliated Hospital with Nanjing Medical University
Ruijin Hospital
Xencor, Inc.
IRCCS San Raffaele
Peking Union Medical College Hospital
MorphoSys AG
Zhejiang Cancer Hospital
Celgene
M.D. Anderson Cancer Center
Centre Hospitalier Universitaire, Amiens
Huazhong University of Science and Technology
The First Affiliated Hospital with Nanjing Medical University
The First Affiliated Hospital with Nanjing Medical University
Institute of Hematology & Blood Diseases Hospital, China
Ruijin Hospital
Ruijin Hospital
Nanfang Hospital, Southern Medical University
Royal Marsden NHS Foundation Trust
Fred Hutchinson Cancer Center
Vanderbilt-Ingram Cancer Center
National Cancer Institute (NCI)
University of Bologna
Celgene